Patients with glaucoma treated with iDose TR experienced sustained IOP reductions. Image: Adobe Stock ... around the globe suffering from chronic eye diseases.” ...

The iDose TR is a sustained-release intracameral implant that delivers travoprost, a prostaglandin analog, directly into the eye. The FDA approved ... the same period. Image Source: Zacks ...

These clinical updates leave us ideally positioned to advance our mission to transform vision therapies for the benefit of patients around the globe suffering from chronic eye diseases.” ...

Additionally, new phase 4 data highlights significant reductions in intraocular pressure when iDose is used alongside ... are designed to reduce intraocular eye pressure by improving aqueous ...

In a new 6-month follow-up analysis of a Phase 4 single-arm clinical study that evaluated 60 open-angle glaucoma patients, iDose TR implanted ... suffering from chronic eye diseases." ...